Sunovion Brochures for COPD Drug Flagged By FDA for Overblown Claims

The FDA has handed Japanese drugmaker Sunovion an untitled letter for overstating efficacy claims about its bronchodilator Brovana in four patient brochures. The letter, posted Oct. 29, singles out statements emblazoned across the brochures trumpeting that patients that take Brovana (arformoterol) “may get back to daily living.”
Washington Drug Letter